Prevalence of reduced bone mineral density in patients with anti-neutrophil cytoplasmic antibody associated vasculitis and the role of immunosuppressive therapy: a cross-sectional study
| Autor: | DA Piers, M Karsijns, MM Boomsma, Coen A. Stegeman, Jwc Tervaert, AB Kramer |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
musculoskeletal diseases
Adult Male Vasculitis medicine.medical_specialty Cyclophosphamide Endocrinology Diabetes and Metabolism Osteoporosis Urology Antibodies Antineutrophil Cytoplasmic Bone Density Internal medicine medicine Humans Femur Glucocorticoids Osteoporosis Postmenopausal Aged Aged 80 and over Analysis of Variance Dose-Response Relationship Drug Cumulative dose business.industry Middle Aged medicine.disease Rheumatology Surgery Osteopenia Cross-Sectional Studies Orthopedic surgery Drug Therapy Combination Female business Immunosuppressive Agents medicine.drug |
| Zdroj: | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 13(1) |
| ISSN: | 0937-941X |
| Popis: | Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a relapsing-remitting disease, which is treated with corticosteroids (CS) in combination with cyclophosphamide. One of the major side-effects of this treatment is osteoporosis, which may result in the increased occurrence of fractures. In the present study we measured the prevalence of reduced bone mineral density (BMD) in a cross-sectional cohort of patients and correlated BMD findings with cumulative doses of CS and/or cyclophosphamide. BMD was measured by dual-energy X-ray absorptiometry (DXA) of the lumbar spine, radius and proximal femur between January 1998 and December 1999. Cumulative doses of CS and cyclophosphamide were calculated by chart review. Ninety-nine consecutive patients (48 men, 51 women) aged 55 +/- 16 years (mean +/- SD) were studied 50 months (median; range 0-400 months) after a diagnosis of ANCA-associated vasculitis had been made. Sixty-nine patients were treated with 10.7 g (median cumulative dose; range 0.4-67.2 g) of CS, and 88 patients were treated with 34.1 g (median cumulative dose; range 0.8-324.3 g) of cyclophosphamide. Fifty-seven percent of the patients had osteopenia (T-score: -1 to -2.5 SD), and 21% had osteoporosis (T-score |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink